Aim: This is a pre-post observational study from an endocrinology ambulatory care practice which assessed the effectiveness and safety following the addition of a glucagon-like peptide-1 (GLP-1) agonist, weekly exenatide (Bydureon), to basal insulin therapy in patients with type 2 diabetes mellitus (T2DM). Liraglutide plus basal insulin served as a comparison group.
| INTRODUCTION
It is estimated that nearly 30 million people in the United States, roughly 10% of the population, have diabetes. 1 Type 2 diabetes mellitus (T2DM), which makes up more than 90% of all diabetes cases, is a heterogeneous and progressive disease typically requiring the use of an increasing number of antidiabetic medications. Good glycaemic control results in a decreased incidence of diabetes-related complications. 2 However, just over half (52.5%) of people with diabetes achieve the American Diabetes Association's (ADA)-recommended HbA 1c of <7% (53 mmol/ mol), and <20% meet combined HbA 1c , blood pressure and lipid goals. in robust glycaemic control with one-third less hypoglycaemia and a significant decrease in weight compared with the addition of prandial insulin. 4 Agents that can improve glycaemic control, have a low risk for hypoglycaemia and promote weight loss are especially desirable in diabetes management.
There are currently five commercially available GLP-1 receptor agonists approved for use within the United States and they include albiglutide, dulaglutide, exenatide, liraglutide and lixisenatide. The first three have once-weekly formulations available and the latter three have twice-or once-daily formulations (exenatide has two formulations available). All agents are currently approved for the management of T2DM as an adjunct to diet and exercise, but albiglutide, dulaglutide and liraglutide are the only long-acting agents approved for concurrent use with basal insulin. [5] [6] [7] [8] [9] [10] Liraglutide is also indicated to reduce the risk for major adverse cardiovascular events in patients with established cardiovascular disease. 9 This is a real-world, pre-post observational study from an ambulatory endocrinology practice that assessed the efficacy and safety following the addition of a GLP-1 receptor agonist (once-weekly exenatide [Bydureon] or once-daily liraglutide [Victoza] ), to the regimens of patients with T2DM who have already received a minimum of 1 year of basal insulin therapy. Liraglutide was chosen as a comparator because it is the market leader for GLP-1 receptor agonists.
We hypothesize that GLP-1 receptor agonist therapy added to basal insulin therapy would result in a statistically significant improvement in glycaemic control and weight loss, with a similar risk of hypoglycaemia compared with baseline.
| MATERIALS AND METHODS
This is a pre-post observational study which assessed the efficacy (48 mmol/mol), changes in systolic and diastolic blood pressure and changes in lipid parameters (TC, LDL-C, TG and HDL-C).
| Statistical analysis
A two-tailed t test was performed to compare outcome differences between the two GLP-1 receptor agonist groups and a P-value of <.05 was considered to be statistically significant. Assuming an HbA 1c change of −0.5% from baseline, a beta error of 0.8 and an alpha error of 0.05, a sample size of 60 patients per group was determined to be required.
| RESULTS
Three hundred and fifty-eight patients were identified from the clinic's EMR as potential subjects for review. After 75 patients in each group were identified as meeting study criteria, further study enrolment ceased, as the predefined sample size (sixty patients per treatment arm) had been met. The baseline characteristics of the study population are presented in Table 1 . Overall, this was an older group of predominately white, moderately controlled patients with T2DM. A similar number of subjects in each group discontinued therapy secondary to adverse events (Table 3) believed to be GLP-1 Hypoglycaemia was reported in 15% of patients during this trial, compared with 17% the year prior to the addition of a GLP-1 analogue.
Specifically, hypoglycaemia was reported by 9 patients during the year prior to the addition of weekly exenatide, compared with 8 during the Mean change in triglycerides from baseline, mg/dL** +1 +2 0
1-y mean HDL-C, mg/dL [SD]
47 [13] 49 [15] 44 [12] Mean change in HDL-C from baseline, mg/dL** 0 +2 −1 HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; GLP-1, glucagon-like peptide-1; SD, standard deviation. Number of subjects discontinuing GLP-1 therapy secondary to adverse effects, n (%)
32 (21) 18 (24) 14 (19) Number of subjects reporting hypoglycaemia, n (%) 23 (15) 8 (11) 15 (20) Number of subjects discontinuing GLP-1 therapy secondary to cost, n (%)
GLP-1, glucagon-like peptide-1. P > .05 for all comparisons.
year of follow-up, and by 16 patients the year prior to initiation of liraglutide, compared with 15 patients during the year of follow-up.
| DISCUSSION
This was a pre-post observational study from an ambulatory endocrinology practice assessing the effectiveness and safety following the addition of a GLP-1 receptor agonist to the regimens of patients with T2DM who had already received a minimum of 1 year of basal insulin therapy. T2DM is a progressive disease that often requires therapeutic intensification using medications that are often associated with weight gain and a higher incidence of hypoglycae- The results of this study are consistent with reported clinical trials.
There are currently results available from four large studies assessing the utility of adding a long-acting GLP-1 receptor agonist to basal insulin. DURATION-7 was a phase III, multicentre, randomized, doubleblind, placebo-controlled study assessing both the efficacy and safety of once-weekly exenatide to placebo in addition to titrated basal insulin glargine in patients with T2DM. 11 The study consisted of an equal number of male and female subjects in their late 50s with an 11-year history of T2DM whose baseline HbA 1c was 8.5% (69 mmol/mol).
Following 28 weeks of treatment, HbA 1c decreased 1% in the onceweekly exenatide arm and −0.2% in the placebo arm (least-square mean difference −0.7%; P < .001). The HARMONY-6 study was a randomized, open-label, noninferiority, 26-week, active-controlled clinical study, which assessed the efficacy of once-weekly albiglutide vs thrice-daily prandial insulin lispro, both as an add-on to basal insulin. 12 The primary end-point was change in HbA 1c from baseline at week 26. HbA 1c decreased by 0.82% in the once-weekly albiglutide arm and 0.66% in the insulin lispro arm (P < .0001 for noninferiority).
The BEGIN: Victoza Add-On study compared once-daily liraglutide vs once-daily insulin aspart with the largest meal of the day in patients with T2DM on basal insulin (degludec) requiring intensification of therapy. 13 At 26 weeks, HbA 1c was reduced by 0.74% in the liraglutide group compared with −0.39% in the insulin aspart group (P = .0024).
AWARD-9 was a multicentre, double-blind, parallel-arm, placebocontrolled study which compared once-weekly dulaglutide in addition to insulin glargine to placebo plus insulin glargine. 14 After 28 weeks, patients' HbA 1c in the dulaglutide arm decreased by 1.44% and those in the placebo arm decreased by 0.67% (P < .001).
The 4B trial by Diamant et al was a randomized, open-label, noninferiority, 30-week study, which was the first to compare a GLP-1, twice-daily exenatide, to thrice-daily insulin lispro, both in addition to insulin glargine. 15 The primary end-point was change in HbA 1c from baseline at week 30. At the end of treatment, HbA 1c decreased by −1.13% in the once-daily exenatide arm and by −1.10% in the thricedaily insulin lispro arm. Twice-daily exenatide was found to be noninferior to thrice-daily insulin when added to a basal insulin regimen (95% confidence interval −0.18-0.11).
Overweight and obesity are well-recognized public health concerns associated with an increased risk for dyslipidaemia, hypertension, T2DM and cardiovascular death. 16 For patients with T2DM, weight loss can be challenging. A patient's background antidiabetic regimen may be responsible, in part, for excess weight as insulin, meglitinides, sulphonylureas and thiazolidinediones are all associated with weight gain. 16, 17 Efforts to reduce weight by as little as 5%
can improve the weight-related complications mentioned above.
18
The 5 pound (2.3 kg) (2%) weight loss observed in this study was similar for both once-weekly exenatide and once-daily liraglutide.
While this may be modest, there was no prandial insulin comparator group. Eng et al reported a mean 12 pound (5.4 kg) higher weight in patients when prandial insulin was added to basal insulin compared with the addition of a GLP-1 receptor agonist. 4 The addition of onceweekly exenatide to basal insulin was associated with an additional 3.3 pound (1.5 kg) weight loss compared with placebo (P < .001).
12
The modest but additional weight loss observed in this study compared with DURATION-7 may be attributable, in part, to a higher baseline body mass index (BMI) (BMI: 38 kg/m 2 vs 33.3 kg/m 2 , respectively). In HARMONY-6, use of albiglutide was associated with a mean 1.6 pound (0.7 kg) decrease in weight compared with a mean 1.8 pound gain in patients receiving insulin lispro. 12 Use of liraglutide in the BEGIN: Victoza Add-On study was associated with a 6.1 pound (2.8 kg) decrease in weight compared with a 2 pound weight gain in the insulin aspart group. 13 Pozzilli et al reported a 4.2 pound (1.9 kg) weight loss and a 1.1 pound (0.5 kg) weight gain in the dulaglutide and placebo arms, respectively, in AWARD-9. 14 prandial insulin was added to basal insulin. 4 In DURATION-7, hypoglycaemia occurred in 29.7% of weekly exenatide-treated subjects and 29% of placebo-treated subjects. 11 There was 47% less documented symptomatic hypoglycaemia in the GLP-1 group compared with the prandial insulin group in the HARMONY 6 study 12 and a reported 87% decrease in hypoglycaemia with GLP-1 therapy vs prandial insulin in the BEGIN: Victoza Add-On study. 13 In AWARD-9, total hypoglycaemia was similar between the two treatment arms (dulaglutide/basal insulin: 54.7%; placebo/basal insulin: 50.7%). 14 Although liraglutide was commercially available 2 years earlier than once-weekly exenatide, aside from weight, body mass index and LDL-C, no other significant differences were found between treatment arms at baseline (eg, age at therapy initiation, duration of T2DM, gender). Finally, data were collected by a retrospective review of an EMR, and only documented adverse reactions were captured.
It is possible that more adverse events occurred than were reported. These preliminary data support the idea that the addition of a GLP-1 receptor agonist to basal insulin is an effective and safe therapeutic strategy to glycaemic control, as demonstrated in previous clinical trials. [11] [12] [13] [14] [15] This study complements results reported in DURATION-7, 11 which was a large-scale randomized trial; however, the utility of the results reported here indicates that in a real-world clinical setting, once-weekly exenatide is safe and efficacious.
In this pre-post observational study, two GLP-1 analogue therapies added to basal insulin were associated with appreciable and comparable reductions in HbA 1c and weight without an increase in hypoglycaemia. These combination therapies were well tolerated.
Overall, weekly exenatide and daily liraglutide therapy appear to be a safe and effective therapeutic add-on to basal insulin in patients with T2DM who are inadequately controlled. 
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